PrecisionLife and Metrodora Institute partner to accelerate the diagnosis and treatment of long COVID, ME/CFS, and other chronic conditions

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases

Targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

The pioneering precision medicine company, PrecisionLife, and leading US multi-specialty healthcare center, Metrodora Institute, are co-investing in a first-of-its-kind partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic diseases including Long COVID, ME/CFS, ALS, Sjögren's syndrome, and many more. The partners will first develop and validate genotypic diagnostics that provide clinicians with an accurate view of a patient’s risk of disease; then, using the molecular profile of their underlying disease mechanisms, report back effective prescribing decisions and drug discovery opportunities to improve patient outcomes.

The partnership builds on PrecisionLife’s unique insights into the mechanisms driving over 50 complex diseases and Metrodora’s deep clinical and research expertise to address a broad range of chronic, complex conditions, offering hope to communities of patients who have been underserved until now. The first products developed will be in Long COVID and ME/CFS building on PrecisionLife’s groundbreaking studies¹,².

“We’ve gone far too long without providing clinicians and patients with an informative readout of the biological drivers associated with these conditions. Moving with unprecedented speed and scale, we will work to rapidly establish this new class of genotypic diagnostic tools paired with targeted clinical trials at Metrodora,” said Rohit Gupta, Metrodora’s Chief Scientific Officer.

The collaboration will extend to the identification and clinical validation of safe and effective drug repurposing candidates associated with disease modifying mechanisms and accelerate the approval of effective new personalized treatments for patients.

“In Metrodora we have a partner that is focused on the diagnosis and treatment of some of the most challenging and intractable diseases,” said Steve Gardner, PrecisionLife's CEO. “With our combined disease insights, patient support and clinical expertise, we're building a powerful engine that will transform the rate at which both new diagnostics and effective therapies can be clinically validated and provided to patient communities that are massively underserved – improving health for millions of people.”

“PrecisionLife's unrivaled understanding of the mechanistic causes of disease enables us to better diagnose individual patients and specify which therapies are most likely to be effective in treating them,” added John Wirthlin, CEO of Metrodora Institute. “Working together we're committed to reimagining treatment for patients with complex neuroimmune axis disorders.”

References 
1. Das, S., Taylor, K., Kozubek, J., Sardell J., Gardner, S. Genetic risk factors for ME/CFS identified using combinatorial analysis J Transl Med 20, 598 (Dec 2022). https://doi.org/10.1186/s12967-022-03815-8 
2. Taylor, K., Pearson, M., Das, S., Sardell, J., Chocian, K., Gardner, S. Genetic risk factors for Severe and Fatigue Dominant long COVID and commonalities with ME/CFS identified by Combinatorial Analysis J Transl Med 21, 775 (Oct 2023). https://doi.org/10.1186/s12967-023-04588-4

About PrecisionLife®

PrecisionLife is a pioneering precision medicine company changing the way the world predicts, prevents, and treats complex chronic diseases by finding better, more personalized treatment options for patients across the biopharma, diagnostics, and healthcare value chain.
Our combinatorial analytics platform understands disease biology better, identifying disease mechanisms that are relevant to specific patients and the drug targets and treatments that would benefit them.

These unique insights enable us to discover new subgroups of patients with mechanism-based patient stratification biomarkers, identify novel treatment opportunities for unmet medical needs, de-risk and accelerate clinical trials, find new applications for existing drug programs, and build highly predictive complementary diagnostics, personalized risk prediction and disease prevention tools.

To learn more about our groundbreaking work, please visit precisionlife.com, and follow us on LinkedIn (@PrecisionLifeAI) and X/Twitter (@PrecisionLifeAI).

About Metrodora Institute

Located in Salt Lake City, Utah, the Metrodora Institute was founded in 2021 with the vision of reimagining care for patients with complex multisystem disorders. Metrodora is uniquely positioned to advance the latest clinical care and develop and commercialize new diagnostic tests and therapeutics for patients living with these often-debilitating conditions. Metrodora Institute has created an innovative offering with a collaborative multidisciplinary approach to medicine. Metrodora currently treats neurological, gastrointestinal, immunological, autoimmune, pain and metabolic disorders.